News & Media
Follow us on our path to driving innovation for immunocompromised people
Press Releases
2024-10-31
Aicuris Initiates First-in-Human Phase 1 Trial with Antiviral Agent AIC468 to Address BK Virus Infections in Kidney Transplant Recipients
Aicuris has initiated its Phase 1 trial to evaluate the safety, tolerability and pharmacokinetics of AIC468, an antiviral ASO, in healthy volunteers.
2024-07-30
Aicuris Appoints Cynthia Wat as Chief Medical Officer
Aicuris has appointed Dr. Cynthia Wat, a highly accomplished pharmaceutical physician with over 25 years of experience, as Chief Medical Officer. Dr. Wat will lead the management and global development of Aicuris’ clinical pipeline of innovative therapeutic candidates.
2024-07-17
Aicuris Announces Milestone Achievements Further Validating its Pipeline of Anti-viral Solutions for Immuno-compromised Patients
Aicuris reached major milestones in 1H 2024 for letermovir (marketed by MSD as PREVYMIS®), pritelivir, and AIC468 highlighting the rapid progress in developing anti-viral solutions for immunocompromised patients.
2024-01-24
Aicuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement
The cooperation provides us with the opportunity to combine exceptional German antiviral research with our development capabilities and clinical expertise to develop novel therapies for immunocompromised patients.
2024-01-09
Aicuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS® for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients
PREVYMIS® received european approval for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk.